

## Celyad Oncology announces September 2021 Conferences Schedule

Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following conferences in September 2021:

### 2021 Wells Fargo Virtual Healthcare Conference

Dates: Thursday, September 9 – Friday, September 10, 2021

Presentation date: Thursday, September 9

Time: 11:20 a.m. ET / 05:20 p.m. CET

Presenter: Filippo Petti, CEO

A webcast link will be available on the **Events** section of the Celyad Oncology **website**.

### H.C. Wainwright 23rd Annual Global Investment Conference

Dates: Monday, September 13 - Wednesday, September 15, 2021

Presentation: On-demand starting September 13, 7 a.m. ET / 1 p.m. CET

Presenter: Filippo Petti, CEO

### Baird's 2021 Virtual Global Healthcare Conference

Dates: Tuesday, September 14 – Wednesday, September 15, 2021

Presentation date: Tuesday, September 14

Time: 3:45 p.m. ET / 9:45 p.m. CET

Presenter: Filippo Petti, CEO

### About Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit [www.celyad.com](http://www.celyad.com).

### Forward-Looking Statement

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the safety and clinical activity of Celyad Oncology's pipelines and financial condition, results of operation and business outlook. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the expected date of the Phase 1 trial initiation by year-end 2020, our development of additional shRNA-based allogeneic candidates from our CYAD-200 series towards clinical trial, and the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology's U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology's actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

### Investor and Media Contacts:

Sara Zelkovic  
Communications & Investor Relations Director  
Celyad Oncology  
[investors@celyad.com](mailto:investors@celyad.com)

Daniel Ferry  
Managing Director  
LifeSci Advisors, LLC  
[daniel@lifesciadvisors.com](mailto:daniel@lifesciadvisors.com)